Genetic testing can predict bladder cancer diagnosis years in advance

Published Date: 17 Mar 2023

Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.

Read Full News

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Bladder Issues Linger in Kids Treated for Ureter Swelling

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

News All Time

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Personalized Decision-Making for Patients With Advanced HSPC

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Discharge prescription mismatch versus inpatient dose significantly increased refill rate

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Non-invasive, no-anesthesia lithotripsy recently gained FDA approval

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

Recommended News For You

Rare Tumor in a Rare Location in Patient With Constipation

Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?

AI-based liquid biopsy shows promise for detecting brain cancer

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share

Alzheimer's Blood Test Gets FDA Clearance

FDA Advisors Recommend Galleri Multicancer Blood Test

Recommended Articles For You

Tremelimumab: A Potential Breakthrough in Cancer Treatment 

Innovative Methods in Oncology in the Digital Era 

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency 

Base Editing for Rare Hematologic Disease: Advances, Mechanisms, and Clinical Implications 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Sugar' signatures help identify and classify pancreatic cancer cell subtypes

2.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

3.

Study: For predicting breast cancer, AI performs better than traditional risk models.

4.

AI tool accurately detects tumor location on breast MRI

5.

Sports for girls are frequently abandoned due to uniform issues.

1.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

2.

Understanding Villous Adenoma: Causes, Symptoms, and Treatments

3.

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders

4.

Blood Aging Profiles in Wellness Screening: Clinical Implications and Emerging Evidence

5.

Digital Tumor-Board Collaboration Platforms: Transforming Multidisciplinary Cancer Care

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Advances in Modern Cancer Treatment

2.

Navigating the Complexities of Ph Negative ALL - Part VI

3.

Understanding Blood Disorders and Their Diagnosis

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

5.

Navigating the Complexities of Ph Negative ALL - Part XIV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot